KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Total Current Liabilities (2020 - 2025)

Ginkgo Bioworks Holdings' Total Current Liabilities history spans 6 years, with the latest figure at $96.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 10.53% year-over-year to $96.0 million; the TTM value through Dec 2025 reached $96.0 million, down 10.53%, while the annual FY2025 figure was $96.0 million, 10.53% down from the prior year.
  • Total Current Liabilities reached $96.0 million in Q4 2025 per DNA's latest filing, down from $115.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $191.7 million in Q1 2023 to a low of $1.4 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $124.6 million, with a median of $129.8 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: surged 11100.25% in 2022, then tumbled 41.79% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $134.8 million in 2021, then rose by 28.35% to $173.0 million in 2022, then dropped by 5.26% to $163.9 million in 2023, then tumbled by 34.54% to $107.3 million in 2024, then fell by 10.53% to $96.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Total Current Liabilities are $96.0 million (Q4 2025), $115.3 million (Q3 2025), and $96.7 million (Q2 2025).